"Syöpäkeskus vastaa syövän onkologisesta hoidosta koko HUS-alueella. Helsingin ja Uudenmaan lisäksi klinikalla hoidetaan myös muualta Suomesta saapuvia, erikoisosaamista vaativia potilaita. Tutkimukset, hoitosuunnitelmat sekä sädehoito toteutetaan pääosin Meilahden klinikalla, leikkaushoidot puolestaan eri kirurgian yksiköissä. Kahvila sijaitsee 1. kerroksessa. Kahvila on suljettu toistaiseksi. Sisääntulokerroksessa (0. kerros) on kahviautomaatti."

During the past decade, Helsinki University Central Hospital; Dept of Oncology conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 6 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Helsinki University Central Hospital; Dept of Oncology" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Boneca Corporation" with 4 trials sponsored, "Finnish Breast Cancer Group" with 2 trials sponsored, "Orion Corporation, Orion Pharma" with 2 trials sponsored and "Pia Osterlund" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Helsinki University Central Hospital; Dept of Oncology" #1 collaborator was "Helsinki University Central Hospital" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Helsinki University Central Hospital; Dept of Oncology" are "Non-Hodgkin's Lymphoma" (3 trials), "Glioblastoma" (2 trials), "Head and Neck Cancer" (2 trials), "Metastatic Colorectal Cancer" (2 trials) and "Neoplasms" (2 trials). Many other conditions were trialed in "Helsinki University Central Hospital; Dept of Oncology" in a lesser frequency.

Most popular intervention types in "Helsinki University Central Hospital; Dept of Oncology" are "Drug" (20 trials), "Other" (4 trials), "Radiation" (4 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (4 trials), "Atezolizumab" (3 trials), "Carboplatin" (3 trials), "Cisplatin" (2 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Helsinki University Central Hospital; Dept of Oncology" are 24 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Helsinki University Central Hospital; Dept of Oncology". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Helsinki University Central Hospital; Dept of Oncology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Helsinki University Central Hospital; Dept of Oncology, 8 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".